If you’ve just found out you have myelodysplastic syndrome (MDS), you’ll surely have lots of questions. You may never have heard of MDS before or known anyone who had it. You may feel a wide ...
Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.
The European Medicines Agency (EMA) has given a positive recommendation for Rytelo ( imetelstat) for the treatment of adult ...
Luspatercept significantly improved hemoglobin levels in non-transfusion-dependent patients with lower-risk myelodysplastic ...
Myelodysplastic syndromes (MDS) affect the way your body makes new red blood cells, white blood cells, and platelets. MDS treatments slow the disease, help relieve symptoms like tiredness and ...
Lenalidomide has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk myelodysplastic syndromes (MDS). However ...
Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...
Myelodysplastic syndrome (MDS) is a rare haematological cancer characterized by abnormal development and maturation (dysplasia) of immature blood cells in the bone marrow, resulting in varying ...
Panelists discuss how frontline luspatercept is emerging as an effective treatment for anemia in lower-risk myelodysplastic syndrome (LR-MDS), demonstrating significant improvements in hemoglobin ...
With a link to specific genetic mutations in myelodysplastic syndromes, tobacco smoking may be associated with disease progression and survival. Tobacco smoking was linked with specific genetic ...
Smokers with myelodysplastic syndromes (MDS) or a precursor condition had elevated levels of genetic mutations linked to the disease, a new study shows. The study also found that heavier smokers ...